These findings suggest that the Gab2-SHP2 axis may be exploited as a novel modulator of TKI sensitivity in CML and as a potential therapeutic target in TKI-resistant disease. This evidence concerns the gene GAB2 and chronic myelogenous leukemia, BCR-ABL1 positive.